Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

249 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY).
Leonardi S, Franzone A, Piccolo R, McFadden E, Vranckx P, Serruys P, Benit E, Liebetrau C, Janssens L, Ferrario M, Zurakowski A, van Geuns RJ, Dominici M, Huber K, Slagboom T, Buszman P, Bolognese L, Tumscitz C, Bryniarski K, Aminian A, Vrolix M, Petrov I, Garg S, Naber C, Prokopczuk J, Hamm C, Steg G, Heg D, Juni P, Windecker S, Valgimigli M. Leonardi S, et al. Among authors: naber c. BMJ Open. 2019 Mar 9;9(3):e026053. doi: 10.1136/bmjopen-2018-026053. BMJ Open. 2019. PMID: 30852547 Free PMC article. Clinical Trial.
Validation of the updated logistic clinical SYNTAX score for all-cause mortality in the GLOBAL LEADERS trial.
Chichareon P, Onuma Y, van Klaveren D, Modolo R, Kogame N, Takahashi K, Chang CC, Tomaniak M, Asano T, Katagiri Y, van Geuns RM, Bolognese L, Tumscitz C, Vrolix M, Petrov I, Garg S, Naber CK, Sabaté M, Iqbal J, Wykrzykowska JJ, Piek JJ, Spitzer E, Jüni P, Hamm C, Steg PG, Valgimigli M, Vranckx P, Windecker S, Serruys PW. Chichareon P, et al. Among authors: naber ck. EuroIntervention. 2019 Aug 9;15(6):e539-e546. doi: 10.4244/EIJ-D-19-00184. EuroIntervention. 2019. PMID: 31217143 Free article. Clinical Trial.
Influence of Bleeding Risk on Outcomes of Radial and Femoral Access for Percutaneous Coronary Intervention: An Analysis From the GLOBAL LEADERS Trial.
Gao C, Buszman P, Buszman P, Chichareon P, Modolo R, Garg S, Takahashi K, Kawashima H, Wang R, Chang CC, Kogame N, Tomaniak M, Ono M, Hara H, Slagboom T, Aminian A, Naber CK, Carrie D, Hamm C, Steg PG, Onuma Y, Geuns RV, Serruys PW, Zurakowski A. Gao C, et al. Among authors: naber ck. Can J Cardiol. 2021 Jan;37(1):122-130. doi: 10.1016/j.cjca.2020.01.029. Epub 2020 Feb 21. Can J Cardiol. 2021. PMID: 32450057 Free article. Clinical Trial.
Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: Per-Protocol Analysis of the GLOBAL LEADERS Trial.
Gragnano F, Zwahlen M, Vranckx P, Heg D, Schmidlin K, Hamm C, Steg PG, Gargiulo G, McFadden EP, Onuma Y, Chichareon P, Benit E, Möllmann H, Janssens L, Leonardi S, Zurakowski A, Arrivi A, Van Geuns RJ, Huber K, Slagboom T, Calabrò P, Serruys PW, Jüni P, Valgimigli M, Windecker S; GLOBAL LEADERS Investigators [Link]. Gragnano F, et al. J Am Heart Assoc. 2022 May 17;11(10):e024291. doi: 10.1161/JAHA.121.024291. Epub 2022 Mar 1. J Am Heart Assoc. 2022. PMID: 35229616 Free PMC article. Clinical Trial.
Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting.
Franzone A, McFadden E, Leonardi S, Piccolo R, Vranckx P, Serruys PW, Benit E, Liebetrau C, Janssens L, Ferrario M, Zurakowski A, Diletti R, Dominici M, Huber K, Slagboom T, Buszman P, Bolognese L, Tumscitz C, Bryniarski K, Aminian A, Vrolix M, Petrov I, Garg S, Naber C, Prokopczuk J, Hamm C, Steg PG, Heg D, Jüni P, Windecker S, Valgimigli M; GLASSY Investigators. Franzone A, et al. Among authors: naber c. J Am Coll Cardiol. 2019 Nov 5;74(18):2223-2234. doi: 10.1016/j.jacc.2019.08.1038. J Am Coll Cardiol. 2019. PMID: 31672177 Free article. Clinical Trial.
PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY.
Gragnano F, Heg D, Franzone A, McFadden EP, Leonardi S, Piccolo R, Vranckx P, Branca M, Serruys PW, Benit E, Liebetrau C, Janssens L, Ferrario M, Zurakowski A, Diletti R, Dominici M, Huber K, Slagboom T, Buszman P, Bolognese L, Tumscitz C, Bryniarski K, Aminian A, Vrolix M, Petrov I, Garg S, Naber C, Prokopczuk J, Hamm C, Steg PG, Jüni P, Windecker S, Valgimigli M. Gragnano F, et al. Among authors: naber c. Eur Heart J Cardiovasc Pharmacother. 2022 Jan 5;8(1):28-38. doi: 10.1093/ehjcvp/pvaa106. Eur Heart J Cardiovasc Pharmacother. 2022. PMID: 32941620 Free article.
Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis.
Valgimigli M, Mehran R, Franzone A, da Costa BR, Baber U, Piccolo R, McFadden EP, Vranckx P, Angiolillo DJ, Leonardi S, Cao D, Dangas GD, Mehta SR, Serruys PW, Gibson CM, Steg GP, Sharma SK, Hamm C, Shlofmitz R, Liebetrau C, Briguori C, Janssens L, Huber K, Ferrario M, Kunadian V, Cohen DJ, Zurakowski A, Oldroyd KG, Yaling H, Dudek D, Sartori S, Kirkham B, Escaned J, Heg D, Windecker S, Pocock S, Jüni P; SIDNEY Collaboration. Valgimigli M, et al. JACC Cardiovasc Interv. 2021 Feb 22;14(4):444-456. doi: 10.1016/j.jcin.2020.11.046. JACC Cardiovasc Interv. 2021. PMID: 33602441 Free article.
2-Year Clinical Outcomes of an Abluminal Groove-Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent.
Xu B, Saito Y, Baumbach A, Kelbæk H, van Royen N, Zheng M, Morel MA, Knaapen P, Slagboom T, Johnson TW, Vlachojannis G, Arkenbout KE, Holmvang L, Janssens L, Ochala A, Brugaletta S, Naber CK, Anderson R, Rittger H, Berti S, Barbato E, Toth GG, Maillard L, Valina C, Buszman P, Thiele H, Schächinger V, Lansky A, Wijns W; TARGET AC Investigators. Xu B, et al. Among authors: naber ck. JACC Cardiovasc Interv. 2019 Sep 9;12(17):1679-1687. doi: 10.1016/j.jcin.2019.05.001. Epub 2019 May 22. JACC Cardiovasc Interv. 2019. PMID: 31129092 Free article. Clinical Trial.
Final results of a self-apposing paclitaxel-eluting stent fOr the PErcutaNeous treatment of de novo lesions in native bifurcated coronary arteries study.
Naber CK, Pyxaras SA, Nef H, IJsselmuiden AJ, Briguori C, Schlundt C, Wykrzykowska J, Eberli FR, Möllmann H, Galatius S, Rieber J, Commeau P, van Geuns RJ, Bouchez D, Mudra H. Naber CK, et al. EuroIntervention. 2016 Jun 20;12(3):356-8. doi: 10.4244/EIJY15M06_02. EuroIntervention. 2016. PMID: 26060087 Free article.
Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for acute coronary syndrome from the DELTA registry: a multicentre registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment.
Pyxaras SA, Hunziker L, Chieffo A, Meliga E, Latib A, Park SJ, Onuma Y, Capranzano P, Valgimigli M, Narbute I, Makkar RR, Palacios IF, Kim YH, Buszman PP, Chakravarty T, Sheiban I, Mehran R, Margey R, Agnihotri A, Marra S, Capodanno D, Leon MB, Moses JW, Fajadet J, Lefevre T, Morice MC, Erglis A, Tamburino C, Alfieri O, Serruys PW, Colombo A, Naber CK. Pyxaras SA, et al. Among authors: naber ck. EuroIntervention. 2016 Aug 5;12(5):e623-31. doi: 10.4244/EIJV12I5A102. EuroIntervention. 2016. PMID: 27497362 Free article.
249 results